Enterome to Present Updated Data From Phase 1/2 ROSALIE Trial of its Peptide-Based Immunotherapy EO2401 in Recurrent Glioblastoma at SNO 2023
November 13, 2023 06:00 ET
|
Enterome
PARIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
Enterome Presents Immune-Monitoring Data on EO2401 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 01, 2023 07:00 ET
|
Enterome
Immune-monitoring data from the ongoing trials of EO2401 in adrenal tumors (SPENCER) and in recurrent glioblastoma (ROSALIE) High degree of homology with TAAs and robust immune responses validate the...
Enterome Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program
October 30, 2023 06:00 ET
|
Enterome
LLS TAP is a strategic funding initiative to accelerate innovative blood cancer therapeutics Strategic equity investment of €3 million to support clinical advancement of EO2463 in Non-Hodgkin’s...
Enterome to Present Clinical Progress on its OncoMimics™ Pipeline at Upcoming Investor Meetings
October 25, 2023 08:33 ET
|
Enterome
PARIS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on...
Enterome Presents Positive Data from Phase 1/2 SPENCER Trial of EO2401 in Adrenal Tumors at ESMO 2023 Congress
October 23, 2023 08:00 ET
|
Enterome
Updated results demonstrate sustained efficacy with a good safety profile Degree of tumor shrinkage on CT scans correlates with strength of CD8+ T cell specific immune response against EO2401...
Enterome to Present Data on EO2401 in Adrenal Tumors at the European Society for Medical Oncology (ESMO) 2023 Congress
October 16, 2023 06:00 ET
|
Enterome
PARIS, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
Enterome announces first patient dosed in Phase 2 trial with OncoMimics™ immunotherapy EO2040 in Colorectal Cancer with ctDNA-defined Minimal Residual Disease
July 11, 2023 06:00 ET
|
Enterome
First clinical trial of an OncoMimics™ immunotherapy to use liquid biopsy monitoring to measure ctDNA clearance as an indicator of treatment efficacy EO2040 is Enterome’s fourth OncoMimics™...
Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer
June 30, 2023 06:00 ET
|
Enterome
EO4010 uniquely mimics five distinct tumor-associated antigens designed to provide multi-targeted, broad tumor coverage, maximizing tumor killing and preventing immune escape Paris, France – June 30,...
Enterome's new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma
June 14, 2023 06:00 ET
|
Enterome
EO2463 uniquely targets four distinct B cell markers to maximize tumor killing and prevent immune escape, generating fast, strong and durable CD8+ T cell activation against malignant B cells ...
Enterome announces sustained positive clinical outcomes with EO2401, its lead OncoMimics™ immunotherapy, in combination therapy in Glioblastoma at ASCO
May 31, 2023 06:00 ET
|
Enterome
Updated clinical data highlight promising efficacy and sustained CD8+ T cell expansion Early data from final cohort could provide validation of the EO2401 + nivolumab + bevacizumab combination...